SEARCH

SEARCH BY CITATION

References

  • 1
    Berman JD. Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clin Infect Dis 1997; 24: 684703.
  • 2
    Bryceson AD. Leishmaniasis. In: CookCG, ed. Manson's Tropical Diseases. London: WB Saunders, 1996: 121345.
  • 3
    Fernandez Guerrero ML, Aguado JM, Buzón L et al. Visceral leishmaniasis in immunocompromised hosts. Am J Med 1987; 83: 1098102.
  • 4
    Berenguer J, Gómez-Campderá F, Padilla B et al. Visceral leishmaniasis (Kala-azar) in transplant recipients. Transplantation 1998; 65: 14014.
  • 5
    World Health Organization. Leishmania/HIV co-infection, south-western Europe, 1990–1998. Retrospective analysis of 965 cases. Wkly Epidemiol Rec 1999; 74: 36576.
  • 6
    World Health Organization. Leishmania/HIV co-infection. Epidemiological analysis of 692 retrospective cases. Wkly Epidemiol Rec 1997; 72: 4954.
  • 7
    World Health Organization. Report on the consultative meeting on Leishmania/HIV co-infection. WHO/LEISH/95.35. Geneva: World Health Organization, 1995: 114.
  • 8
    Rosenthal E, Marty P, Le-Fichoux Y, Cassuto J. Clinical manifestations of visceral leishmaniasis associated with HIV infection: a retrospective study of 91 French cases. Ann Trop Med Parasitol 2000; 94: 3742.DOI: 10.1080/00034980057590
  • 9
    Rosenthal E, Marty P, Poizot MI et al. Visceral leishmaniasis and HIV-1 co-infection in southern France. Trans R Soc Trop Med Hyg 1995; 89: 15962.
  • 10
    Gradoni L, Scalone A, Gramiccia M, Troiani M. Epidemiological surveillance of leishmaniasis in HIV-1-infected individuals in Italy. AIDS 1996; 10: 78591.
  • 11
    Agostoni C, Dorigoni N, Malfitano A et al. Mediterranean leishmaniasis in HIV-infected patients: epidemiological, clinical, and diagnostic features of 22 cases. Infection 1998; 26: 939.
  • 12
    Peters BS, Fish D, Golden R, Evans DA, Bryceson AD, Pinching AJ. Visceral leishmaniasis in HIV infection and AIDS: clinical features and response to therapy. Q J Med 1990; 77: 110111.
  • 13
    Albrecht H, Sobottka I, Emminger C et al. Visceral leishmaniasis emerging as an important opportunistic infection in HIV-infected persons living in areas nonendemic for Leishmania donovani. Arch Pathol Lab Med 1996; 120: 18998.
  • 14
    Dereure J, Reynes J, Pratlong F et al. Visceral leishmaniasis in HIV-infected patients in the south of France. Bull WHO 1995; 73: 2456.
  • 15
    Cabie A, Matheron S, Lepretre A, Bouchaud O, Deluol AM, Coulaud JP. Visceral leishmaniasis in HIV infection. A totally opportunistic infection. Presse Med 1992; 21: 165862.
  • 16
    Pasquau F, Ena J, Sanchez R, the Mediterranean Group for Leishmania–HIV Study. Leishmania and HIV infection: a collaborative study of 228 episodes in a Spanish Mediterranean area. 13th International AIDS Conference, Durban, South Africa, 2000. Abstract TuOrB357.
  • 17
    Pintado V, Martín-Rabadán P, Rivera ML, Moreno S, Bouza E. Visceral leishmaniasis in HIV-infected and non-HIV-infected patients: a comparative study. Medicine (Baltimore) 2001; 80: 5473.
  • 18
    López-Vélez R, Pérez-Molina JA, Guerrero A et al. Clinico-epidemiological characteristics, prognostic factors and survival analysis of patients co-infected with HIV and Leishmania in an area of Madrid, Spain. Am J Trop Med Hyg 1998; 58: 43643.
  • 19
    Medrano FJ, Hernández-Quero J, Jiménez E et al. Visceral leishmaniasis in HIV-1-infected individuals: a common opportunistic infection in Spain? AIDS 1992; 6: 1499503.
  • 20
    Laguna F, Adrados M, Alvar J et al. Visceral leishmaniasis in patients infected with the human immunodeficiency virus. Eur J Clin Microbiol Infect Dis 1997; 16: 898903.
  • 21
    Montalban C, Calleja JL, Erice A et al. Visceral leishmaniasis in patients infected with human immunodeficiency virus. Co-operative Group for the Study of Leishmaniasis in AIDS. J Infect 1990; 21: 26170.
  • 22
    Jover F, Cuadrado JM, Andreu L et al. Visceral leishmaniasis in HIV patients: clinical experience of 8 years. Enferm Infec Microbiol Clin 2000; 18 (supl. 1): 878.
  • 23
    Ribera E, Cucurull E, Ocana I, Vallespi T, Gasser I, Juste C. Visceral leishmaniasis in patients with HIV infection. Enferm Infecc Microbiol Clin 1995; 13: 739.
  • 24
    Reus S, Sánchez R, Portilla J et al. Visceral leishmaniasis: comparative study in patients with and without HIV infection. Enferm Infecc Microbiol Clin 1999; 17: 51520.
  • 25
    Sanz M, Rubio R, Casillas A, Costa JR, Martínez R, De Dios JG. Visceral leishmaniasis in HIV-infected patients. AIDS 1991; 5: 12724.
  • 26
    Berenguer J, Moreno S, Cercenado E, Bernaldo de Quirós JCL, Fuente AG, Bouza E. Visceral leishmaniasis in patients infected with human immunodeficiency virus (HIV). Ann Intern Med 1989; 111: 12932.
  • 27
    Alvar J, Canavate C, Gutierrez SB et al. Leishmania and human immunodeficiency virus coinfection: the first 10 years. Clin Microbiol Rev 1997; 10: 298319.
  • 28
    Gradoni L, Bryceson AD, Desjeux P. Treatment of Mediterranean visceral leishmaniasis. Bull WHO 1995; 73: 1917.
  • 29
    Kubar J, Marty P, Lelievre A et al. Visceral leishmaniasis in HIV-positive patients: primary infection, reactivation and latent infection. Impact of the CD4+ T-lymphocyte counts. AIDS 1998; 12: 214753.
  • 30
    Pineda JA, Gallardo JA, Macias J et al. Prevalence of and factors associated with visceral leishmaniasis in human immunodeficiency virus type 1-infected patients in southern Spain. J Clin Microbiol 1998; 36: 241922.
  • 31
    Gradoni L, Scalone A, Gramiccia M. HIV-Leishmania co-infections in Italy: serological data as an indication of the sequence of acquisition of the two infections. Trans R Soc Trop Med Hyg 1993; 87: 946.
  • 32
    Pratlong F, Dedet JP, Marty P et al. Leishmania–human immunodeficiency virus coinfection in the Mediterranean basin: isoenzymatic characterization of 100 isolates of the Leishmania infantum complex. J Infect Dis 1995; 172: 3236.
  • 33
    Miralles P, Moreno S, Pérez-Tascón M, Cosin J, Díaz MD, Bouza E. Fever of uncertain origin in patients infected with the human immunodeficiency virus. Clin Infect Dis 1995; 20: 8725.
  • 34
    Pulido F & Laguna F, the GESIDA-SEIMC Study Group. Atypical locations of leishmaniasis in HIV-infected patients [abstract 35-11]. In: 8th Congress of the Spanish Society of Infectious Diseases and Clinical Microbiology. Palma de Mallorca, Spain: 1998.
  • 35
    López-Vélez R, Laguna F, Alvar J et al. Parasitic culture of buffy coat for diagnosis of visceral leishmaniasis in human immunodeficiency virus-infected patients. J Clin Microbiol 1995; 33: 9379.
  • 36
    Molina R, Canavate C, Cercenado E, Laguna F, López-Vélez R, Alvar J. Indirect xenodiagnosis of visceral leishmaniasis in 10 HIV-infected patients using colonized Phlebotomus perniciosus. AIDS 1994; 8: 2779.
  • 37
    Izri MA, Deniau M, Briere C et al. Leishmaniasis in AIDS patients: results of leukocytoconcentration, a fast biological method of diagnosis. Bull WHO 1996; 74: 913.
  • 38
    Lachaud L, Dereure J, Chabbert E et al. Optimized PCR using patient blood samples for diagnosis and follow-up of visceral leishmaniasis, with special reference to AIDS patients. J Clin Microbiol 2000; 38: 23640.
  • 39
    Piarroux R, Gambarelli F, Dumon H et al. Comparison of PCR with direct examination of bone marrow aspiration, myeloculture, and serology for diagnosis of visceral leishmaniasis in immunocompromised patients. J Clin Microbiol 1994; 32: 7469.
  • 40
    Medrano FJ, Canavate C, Leal M, Rey C, Lissen E, Alvar J. The role of serology in the diagnosis and prognosis of visceral leishmaniasis in patients coinfected with human immunodeficiency virus type-1. Am J Trop Med Hyg 1998; 59: 15562.
  • 41
    Altes J, Salas A, Riera M et al. Visceral leishmaniasis: another HIV-associated opportunistic infection? Report of eight cases and review of literature. AIDS 1991; 5: 2017.
  • 42
    Herwaldt B & Berman J. Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies. Am J Trop Med Hyg 1992; 46: 296306.
  • 43
    Laguna F, López-Vélez R, Soriano V, Montilla P, Alvar J, González-Lahoz J. Assessment of allopurinol plus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV. J Infect 1994; 28: 2559.
  • 44
    Laguna F, López-Vélez R, Pulido F et al. Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B. AIDS 1999; 13: 10639.
  • 45
    Davidson RN, Martino L, Gradoni L et al. Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: a multi-centre trial. Q J Med 1994; 87: 7581.
  • 46
    Russo R, Nigro L, Minniti S et al. Visceral leishmaniasis in HIV infected patients: treatment with high dose liposomal amphotericin B (AmBisome). J Infect 1996; 32: 1337.
  • 47
    Górgolas M, Castrillo JM, Fernández Guerrero ML. Visceral leishmaniasis in patients with AIDS. Report of three cases treated with pentavalent antimony and interferon-γ. Clin Infect Dis 1993; 17: 568.
  • 48
    Laguna F, Torre CJ, Moreno V, Villanueva JL, Valencia E. Efficacy of intermittent liposomal amphotericin B in the treatment of visceral leishmaniasis in patients infected with human immunodeficiency virus. Clin Infect Dis 1995; 87: 71112.
  • 49
    Ribera E, Ocaña I, De Otero J, Cortés E, Gasser I, Pahissa A. Prophylaxis of visceral leishmaniasis in human immunodeficiency virus-infected patients. Am J Med 1996; 100: 496501.DOI: 10.1016/s0002-9343(97)89503-4
  • 50
    Delgado FM, Garcia OM, Martos PF, Reguera IJ, Jimenez OF, Colmenero CJ. The clinical and evolutional characteristics of visceral leishmaniasis in patients with HIV infection. An Med Int 1997; 14: 50610.
  • 51
    López Dupla JM, Gil A, Lavilla P et al. Efficacy of liposomal amphotericin B in the treatment and secondary prophylaxis of visceral leishmaniasis in HIV infected patients: report of two cases. J Antimicrob Chemother 1993; 32: 6579.
  • 52
    Davidson RN & Konecny P. Immunology and treatment of leishmaniases. Curr Opin Infect Dis 1995; 8: 33641.
  • 53
    Cacopardo B, Nigro L, Preiser W et al. Prolonged Th2 cell activation and increased viral replication in HIV–Leishmania co-infected patients despite treatment. Trans R Soc Trop Med Hyg 1996; 90: 4345.
  • 54
    Berhe N, Wolday D, Hailu A et al. HIV viral load and response to antileishmanial chemotherapy in co-infected patients. AIDS 1999; 13: 19215.
  • 55
    López-Vélez R, Casado JL, Pintado V. Decline of a visceral leishmaniasis epidemic in HIV-infected patients after the introduction of highly active antiretroviral therapy (HAART). Clin Microbiol Infect 2001; 7: 2701.
  • 56
    Tacconelli E, Tumbarello M, Bertagnolio S, Cauda R. Highly active antiretroviral therapy (HAART) decreases the incidence of visceral leishmaniasis in HIV-infected subjects [abstract WePeA4030]. In: Program and Abstracts of the 13th International AIDS Conference, Durban, South Africa, 2000.
  • 57
    Pintado V, Moreno S, Miralles P, Pérez-Tascón M, García JJ, Bouza E. Prolonged survival after highly active antiretroviral therapy (HAART) in AIDS-associated visceral leishmaniasis [abstract WePeA4025]. In: Program and Abstracts of the 13th International AIDS Conference, Durban, South Africa, 2000.
  • 58
    Berenguer J, Cosin J, Miralles P, López JC, Padilla B. Discontinuation of anti-leishmania prophylaxis in HIV-infected patients who have responded to highly active antiretroviral therapy. AIDS 2000; 14: 29468.
  • 59
    Casado JL, López-Vélez R, Pintado V et al. Relapsing visceral leishmaniasis in HIV-infected patients undergoing successful protease inhibitor therapy. Eur J Clin Microbiol Infect Dis 2001; 20: 2025.
  • 60
    Villanueva JL, Cordero E, Bernabeu-Wittel M, Alarcón A, Jiménez E, Pachón J. Visceral leishmaniasis in patients coinfected with HIV in the (HAART) era [abstract I-137]. In: Program and Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy,. San Francisco, CA. Washington DC: American Society for Microbiology, 1999; 459.